Clinical trials: Hepatitis C Virus (HCV)
HCV Infection
Metabolic Viral Host Properties
Patients' metabolic properties may affect their immune response. This study aims to assess the effect of hosts' metabolic properties to viral infection.
- Trial name
- NCT00893308
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Hepatitis C, Testing
Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia
Objectives Principal objective: to compare the effectiveness of a community-based intervention to a facility-based intervention to improve the combined-testing uptake (Antibody + RNA) of HCV infection among general population…
- Trial name
- Cam-C (NCT03992313)
- Testing
- Community-based HCV rapid test, Facility-based HCV rapid test, Plasmatic HCV viral load
- Where
- 2 sites in Cambodia
- Volunteers
- 7,692 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV Recurrence, Liver Transplantation
Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection
The purpose of this study is to evaluate the efficacy, safety and tolerability of direct-acting antivirals therapy in liver transplanted patients who experienced HCV recurrence.
- Conditions
- HCV Recurrence, Liver Transplantation, Direct-acting Antiviral Agents
- Trial name
- ANRSCO23CUPILT (NCT01944527)
- Where
- France
- Volunteers
- 699 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C
A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C
This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the…
- Trial name
- NCT01908335
- Testing
- PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose
- Where
- 52 sites in China
- Volunteers
- 212 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Hepatitis C
Qualification of Point-of-Care Assays for Management of HCV Patients
Acute or chronic HCV infection can lead to liver complications, including liver failure, cirrhosis or liver cancer. For patients with hepatitis C infection, the major clinical question remains the terms of treatment initiation.
- Trial name
- ANRS HC POC (NCT02335320)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
A phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the combined single dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir \& Ribavirin) versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a…
- Trial name
- NCT03186313
- Testing
- Dactavira Plus, Sofosbuvir + Daclatasvir + Ribavirin, Dactavira
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Egyptian Liver Hospital
HIV Infections, Hepatitis C
Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis
The purpose of this study is to look at how 2 different anti-HIV drug treatments affect the liver. The use of anti-HIV drugs like the nucleoside reverse transcriptase inhibitors (NRTIs) may be linked to liver problems like fatty…
- Trial name
- NCT00023218
- Testing
- Lopinavir/Ritonavir, Efavirenz
- Where
- 3 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HCV Infection
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333
The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-333 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of…
- Trial name
- NCT00768690
- Testing
- ABT-333, ketoconazole
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Abbott
Chronic Hepatitis C
An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C
This study is a two-way, non-interventional long-term dynamic follow-up clinical observational cohort study. In the Second Division of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, chronic hepatitis C…
- Trial name
- NCT04301882
- Testing
- interferon combined with ribavirin (PR) antiviral therapy, direct antiviral drugs (DAAs)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Ditan Hospital
Chronic Hepatitis C
Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C
Menopause represents a critical period in a woman's life as the hormonal changes and the failing ovarian function not only determine relevant modifications in the reproductive function but also in many other conditions and organs…
- Trial name
- MEN_EPID (NCT01402583)
- Testing
- PEG IFN/Ribavirin
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Prof. Facchinetti Fabio
Hepatitis C
Identification to Elimination in HCV-Infected Individuals
Approximately 3.5 - 5 million Americans are living with hepatitis C virus (HCV) in the United States. HCV significantly impacts rural Pennsylvania. It is estimated that 160,000 adults in Pennsylvania are living with hepatitis C.
- Trial name
- NCT03195205
- Testing
- OraQuick HCV Rapid Antibody Test
- Where
- United States
- Volunteers
- 3,051 people, healthy volunteers welcome
- Sponsor
- TruCare Internal Medicine & Infectious Disease
Chronic Hepatitis C
Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)
This study will evaluate the technical feasibility of using fine needle aspiration (FNA) of liver tissue to obtain vaniprevir (MK-7009) liver pharmacokinetic (PK) data, working towards identifying a minimally invasive…
- Trial name
- NCT01678131
- Testing
- Vaniprevir 600 mg, Peg-IFN alfa-2b, Ribavirin
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis c
Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents
The primary objective of this study is to prospectively analyse psychiatric outcomes, specifically depression and anxiety in patients with hepatitis C virus infection who are initiated on DAA therapy (sofosbuvir based regimen).
- Trial name
- NCT03894696
- Testing
- Direct Acting Antivirals
- Volunteers
- 200 people
- Sponsor
- Assiut University
Hepatitis C Virus Infection
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in adults with chronic hepatitis C virus (HCV)…
- Trial name
- NCT04112303
- Testing
- SOF/VEL
- Where
- 22 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Gilead Sciences
Hepatitis C
Expression of Inflammasomes in HCV Patients
Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma.
- Trial name
- Inflammasome (NCT04244383)
- Testing
- interleukin IL-1beta and interleukin IL-18
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Genotype 1 Hepatitis C Virus
Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
To determine the efficacy and safety of Harvoni in treatment-naïve alcoholic subjects with Genotype 1 HCV infection
- Trial name
- NCT02759861
- Testing
- harvoni
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Nebraska
Chronic Hepatitis C, Hepatitis, Viral, Human
Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
The purpose of this study is to assess the safety and efficacy of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1.
- Trial name
- NCT00230854
- Testing
- EMZ702
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- OPKO Health, Inc.
Hepatic Impairment
Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
This is an open-label, single-dose study designed to assess the pharmacokinetics and safety of ABT-493 and/or ABT-530 in subjects with impaired hepatic function and compare them to those in subjects with normal hepatic function.
- Trial name
- NCT02296905
- Testing
- ABT-493, ABT-530
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Liver Disease Chronic, HEPATITIS C VIRUS CHRONIC INFECTION
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
The purpose of this clinical trial is to evaluate whether a nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein improves biochemical and molecular markers, as well as clinical outcomes, in…
- Trial name
- RESQUETI (NCT07487623)
- Testing
- resveratrol, quercetin, taurine, whey protein, and inulin, whey protein
- Where
- 2 sites in Mexico
- Volunteers
- 26 people
- Sponsor
- University of Guadalajara
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.